Stock 4556 KAINOS LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News KAINOS Laboratories, Inc.

Equities

4556

JP3205650009

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
1,152 JPY +1.68% Intraday chart for KAINOS Laboratories, Inc. -4.64% +5.59%
2022 KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation CI
2022 KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation
CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation
CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.
CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.
CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.
CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.
CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.
CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2020, has closed with 88,000 shares, representing 2.02% for ¥90.29 million.
CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 90,000 shares, representing 2.02% for ¥100 million.
CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.
CI
KAINOS Laboratories, Inc. announced that it has received ¥435.12 million in funding from Asahi Kasei Pharma Corporation
CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥435.12 million in funding from Asahi Kasei Pharma Corporation
CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on September 25, 2018.
CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on September 25, 2018 has expired with 490,800 shares, representing 11.01% for ¥541.35 million. The company repurchased 490,800 shares from Hitachi Chemical Company, Ltd..
CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 500,000 shares, representing 11.22% for ¥551.5 million.
CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.
CI
Kainos Laboratories, Inc. announced that it has received ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm.
CI
Kainos Laboratories, Inc. announced that it expects to receive ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm.
CI
Tranche Update on Kainos Laboratories, Inc.'s Equity Buyback Plan announced on August 25, 2015.
CI
Kainos Laboratories, Inc.'s Equity Buyback announced on August 25, 2015, has expired with repurchase of 270,000 shares, representing 6.07% for ¥160.65 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4556 Stock
  4. News KAINOS Laboratories, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW